A*STAR and Public Research Institutes
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public-sector research and development agency. It is a statutory board under the Ministry of Trade and Industry (MTI) and operates research institutes spanning biomedical sciences and physical sciences and engineering, with research entities primarily located at Biopolis and Fusionopolis (MTI, accessed Aug 2026; A*STAR About, accessed Aug 2026). ASTAR describes itself as a science and technology organisation that bridges academia and industry, collaborates with public and private partners, and nurtures scientific talent for research institutes, the wider research community, and industry (A*STAR About, accessed Aug 2026). This article explains ASTAR's institutional role, institute structure, and how that differs from national Research, Innovation and Enterprise (RIE) policy funding led by the National Research Foundation (NRF). Industry-facing biomedical manufacturing context sits in biomedical and pharma; university teaching and admissions sit in universities.
Statutory status and mission
ASTAR is a statutory board under the Ministry of Trade and Industry (MTI), which lists it among the ministry's statutory boards whose work includes driving research and innovation (MTI, accessed Aug 2026; see also statutory boards). ASTAR describes its role as a public-sector science and technology organisation that bridges academia and industry, develops talent, and pursues research with economic and societal outcomes (A*STAR About, accessed Aug 2026).
A*STAR's published mission is to advance science and develop innovative technology to further economic growth and improve lives, with research aimed at growth and jobs as well as societal outcomes in healthcare, urban living, and sustainability (A*STAR About, accessed Aug 2026). The agency states that it works with other public-sector agencies to develop industry sectors by integrating capabilities for multinational and globally competitive companies, partnering local enterprises, and nurturing R&D-driven start-ups (A*STAR About, accessed Aug 2026). Those mission statements describe organisational purpose; they are not a substitute for dated national RIE budget envelopes published under NRF/RIEC processes.
Biomedical and science-engineering institute structure
A*STAR organises research through research institutes, national centres, and programmes under key divisions that include the Biomedical Research Council (BMRC), the Science and Engineering Research Council (SERC), and Innovation and Enterprise (I&E) (A*STAR organisation structure, accessed Aug 2026). BMRC advances biosciences and bio-innovation for health outcomes and Singapore's biomedical economy, is located at Biopolis, and oversees core capabilities such as bioprocessing, genomics and proteomics, molecular and cell biology, bioengineering and nanotechnology, and computational biology, while also supporting biomedical research in universities and hospitals (A*STAR organisation structure, accessed Aug 2026). SERC promotes public-sector research in the physical sciences and engineering — including communications, materials, chemicals, computational sciences, microelectronics, advanced manufacturing, and metrology — and engages industry partners to move technologies toward commercialisation (A*STAR organisation structure, accessed Aug 2026). I&E translates research into impact through industry partnerships, licensing, venture building, and start-up creation (A*STAR organisation structure, accessed Aug 2026).
As listed on ASTAR's public research-entities directory when accessed in August 2026, biomedical research institutes include the Bioinformatics Institute (BII), Bioprocessing Technology Institute (BTI), Genome Institute of Singapore (GIS), Infectious Diseases Labs (IDL), Institute for Human Development and Potential (IHDP), Institute of Molecular and Cell Biology (IMCB), Singapore Immunology Network (SIgN), Singapore Institute of Food and Biotechnology Innovation (SIFBI), and Skin Research Labs (SRL) (A*STAR home, accessed Aug 2026). Science and engineering research institutes listed at the same time include the Advanced Remanufacturing and Technology Centre (ARTC), Institute of Advanced Intelligence and Computing (IAIC), Institute of Microelectronics (IME), Institute of Materials Research and Engineering (IMRE), Institute of Sustainability for Chemicals, Energy and Environment (ISCE²), National Metrology Centre (NMC), and Singapore Institute of Manufacturing Technology (SIMTech) (A*STAR home, accessed Aug 2026). Institute names and groupings change over time; treat the live ASTAR directory as authoritative for the current inventory, and use astar research entities for a compact identity table tied to that access date.
Institute of Advanced Intelligence and Computing
On 1 July 2026, ASTAR announced the formation of the **ASTAR Institute of Advanced Intelligence and Computing** (IAIC) through the integration of the Institute for Infocomm Research (I²R) and the Institute of High Performance Computing (IHPC) (A*STAR statement, 1 July 2026). The new institute brings together capabilities in artificial intelligence, data and digital technologies, modelling and simulation, quantum computing, and high-performance computing. A*STAR described IAIC as supporting AI and digital solutions across research, industry, and the public sector; this is an institutional formation statement, not evidence that every named capability is a separate institute or that all AI work in Singapore sits within IAIC.
IAIC is therefore a current ASTAR institute identity within the science-and-engineering portfolio, while this article remains the right place to explain ASTAR's statutory status, BMRC/SERC structure, and relationship to NRF. The 1 July announcement says IAIC was formed by integrating I²R and IHPC; it does not establish a new national AI regulator, a separate university, or a replacement for AI Singapore.
Universities, hospitals, and industry
ASTAR positions its institutes inside a wider public research system rather than as a closed laboratory network. BMRC states that it supports biomedical research in the wider scientific community such as public universities and hospitals, promotes translational and cross-disciplinary work, and crafts partnership programmes intended to attract private biomedical R&D investment into Singapore (A*STAR organisation structure, accessed Aug 2026). SERC similarly plans multidisciplinary collaborations across industries, institutes, and sectors, and cultivates industry partners through funding schemes and attachment programmes so technologies can move from conception toward commercialisation (A*STAR organisation structure, accessed Aug 2026). ASTAR's about page frames the agency as bridging academia and industry and as a catalyst and convenor of research initiatives among partners in Singapore and beyond (A*STAR About, accessed Aug 2026).
In practice, that means ASTAR institutes are public research performers that collaborate with autonomous universities, clinical partners, multinational corporations, local enterprises, and start-ups, while I&E handles licensing and venture pathways (A*STAR About, accessed Aug 2026; A*STAR organisation structure, accessed Aug 2026). University degree programmes, faculty appointments, and admissions remain under the higher-education system documented in universities; ASTAR's role is research performance, talent pipelines into research and industry, and translation — not substituting for university governance. Biomedical manufacturing parks, plant investment, and therapeutic-product licensing are covered in biomedical and pharma and should not be collapsed into A*STAR institute identity alone.
Critical perspectives: NRF policy funding versus A*STAR performance
The National Research Foundation is a department within the Prime Minister's Office, established on 1 January 2006. NRF sets national direction for research and development by developing policies, plans, and strategies for research, innovation, and enterprise; it also funds strategic initiatives and develops R&D capabilities by nurturing research talent (NRF, accessed Aug 2026). Singapore's multi-year Research, Innovation and Enterprise plans are the high-level funding and priority framework for that ecosystem. At a 5 December 2025 press conference launching RIE2030, the Government announced investment of S$37 billion over the next five years from April 2026 — described as about one per cent of GDP — continuing the sequence of five-year RIE and earlier science and technology plans (PMO, 5 Dec 2025, accessed Aug 2026).
ASTAR is a major public research performer and translation agency inside that ecosystem, not the national RIE policy owner. NRF sets direction and funds strategic initiatives; ASTAR runs institutes, partners with universities and firms, and commercialises outputs under MTI oversight and its own statute (NRF, accessed Aug 2026; MTI, accessed Aug 2026; A*STAR About, accessed Aug 2026). Do not treat an ASTAR institute budget, a university grant, or a corporate laboratory announcement as the whole RIE envelope, and do not treat NRF as the operator of Biopolis or Fusionopolis institutes. For dated national plan figures, cite the RIE announcement itself; for which institute exists under BMRC or SERC, cite ASTAR's current directory rather than undated secondary summaries.